Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2003-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more tumor cells.
Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of
chemotherapy.
PURPOSE: Phase I trial to study the effectiveness of amifostine in treating patients with
newly diagnosed acute myeloid leukemia who are receiving idarubicin plus cytarabine.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University